Cerebral accumulation of b-amyloid peptide (Ab) is a central event in the pathogenesis of Alzheimer's disease (AD). Endothelin-converting enzyme-1 (ECE-1) is a candidate Ab-degrading enzyme in brain, but its involvement in AD pathogenesis was never assessed. We first performed brain immunocytochemistry, using a monoclonal anti-ECE-1 antibody, and observed neuronal ECE-1 expression in various cortical regions of nondemented subjects. In the hippocampus, ECE-1 immunoreactivity showed a stereotypical pattern inversely correlated with susceptibility to Ab deposition, further suggesting a physiological role in Ab clearance. In order to undertake a genetic association study, we identified a functional genetic variant (ECE1B C-338A) located in a regulatory region of the ECE1 gene. We showed that the A allele is associated with increased transcriptional activity in promoter-reporter gene assays and with increased ECE-1 mRNA expression in human neocortex. In a case-control study involving 401 patients with late-onset AD and 461 aged controls, we found that homozygous carriers of the A allele had a reduced risk of AD (OR ¼ 0.47, 95% CI 0.25-0.88). This finding was strengthened by the analysis of two other genetic variants of the ECE1 gene, which showed that the genetic association is extended over at least 13 kilobases of the gene sequence. Our results suggest that ECE-1 expression in brain may be critical for cortical Ab clearance and offer new potential targets for therapeutic interventions in AD.
Several lines of evidence support an early pathogenic role for the b-amyloid peptide (Ab) in Alzheimer's disease (AD). [1] [2] [3] Ab is a physiological peptide continuously synthesized in brain, produced by cleavage of the amyloid precursor protein (APP). In familial cases of early-onset AD, various mutations of the genes encoding APP and presenilins have been shown to increase Ab production. 3, 4 By contrast, the mechanisms of cortical Ab accumulation in late-onset AD (LOAD) patients appear to be more complex and may involve increased expression and activity of the b-site APP-cleaving enzyme (BACE-1), [5] [6] [7] increased aggregation of Ab fibrils or decreased Ab clearance. 8 Several proteases were shown to hydrolyze Ab in vitro or in cell-based assays, and are likely candidates for a role in Ab clearance in brain. 9, 10 Among these, only four zinc metalloproteases: neprilysin (EC 3.4.24.11), endothelin-converting enzyme-1 (ECE-1, EC 3.4.24.71), endothelin-converting enzyme-2 (ECE-2) and insulysin (EC 3.4.24.56), have been shown to influence endogenous Ab levels in the brains of their respective knockout mice. [11] [12] [13] [14] Neprilysin, ECE-1 and ECE-2 are type II integral membrane peptidases, classified as members of the M13 family, 15 whereas insulysin is a cytosolic enzyme belonging to the M16 family. 16 The four enzymes are suspected to have a physiological role in Ab clearance in human brain, and therefore to protect against development of AD, but direct evidence of their involvement in AD pathogenesis is lacking. Neprilysin immunoreactivity appears to be weak or undetectable in human cerebral cortex. 17, 18 By contrast, insulysin immunoreactivity is marked in hippocampal and neocortical neurons. 19, 20 Several genetic association studies tested for an association between neprilysin or insulysin gene variants and AD, but gave controversial results. [21] [22] [23] [24] [25] To date, the expression of ECE-1 in human brain had never been studied, and its potential role in the pathogenesis of AD had never been assessed. We have addressed this question by a combination of expression and genetic studies, and provide evidence for a protective role of ECE-1 against AD in the aging brain.
Materials and methods

Brain immunocytochemistry
Brains from eight nondemented subjects were studied. Ages at death were 38, 56, 82, 84, 85, 86, 92 and 99 years. Brain specimens were fixed in 10% formaldehyde and embedded in paraffin. ECE-1 immunocytochemistry (ICC) was performed using mouse monoclonal antibodies directed against ECE-1 common C-terminal sequence (B61/104, diluted 1 : 50, and E15/6, diluted 1 : 20) . It was previously shown that both antibodies are specific of ECE-1. 26 However, we did not test these antibodies against the ECE-2 protein, which has B60% identity with ECE-1. Sections were microwaved in citrate buffer, followed by endogenous peroxydases inactivation (3% H 2 O 2 ) and treatment with the blocking agent from the universal HRP immunostaining kit (Immunotech). Primary antibody was identified with a biotinylated secondary antibody and the avidin-biotin complex, and visualized with 3,3-diaminobenzidine. Immunostained paraffin sections were counterstained with hemalun. The level of ECE-1 staining in the various regions was assessed as low (
Polymorphism screening
Genomic DNA was extracted from peripheral whole blood using standard techniques. For each of the three promoter regions of the ECE1 gene, B1000 base pairs (bp) of genomic DNA were amplified by polymerase chain reaction (PCR) in 30 healthy individuals, using AmpliTaq Gold (Perkin-Elmer), as described previously (ECE-1a, ECE-1c), 27 or GC-RICH PCR System (Roche Diagnostics), following manufacturer's instructions (ECE-1b-ECE-1d). PCR products were screened for sequence variations by direct sequencing on a Li-Cor 4000L automated DNA sequencer, as described previously. 27 Wild-type and variant sequences were analyzed for cis-elements using the computer program MatInspector (http://transfac. gbf.de/TRANSFAC). 28 Reporter gene assays All nucleotide positions (np) are given with respect to the ECE-1b translation start site. Genomic DNAs from two subjects (one homozygous for the A allele and the other for the C allele of the ECE1B C-338A polymorphism) were used for promoter activity assays. Genomic DNA regions between np À823 and À2, and between À823 and þ 258 (encompassing the entire ECE-1d-specific promoter sequence) were subcloned into the promoterless pSEAP2-Basic vector (Great EscAPe SEAP Reporter System 3, Clontech) upstream from the SEAP (Secreted Alkaline Phosphatase) gene. Sequencing of the vectors confirmed that the C/A variation was the only sequence change. The four gene constructs were transiently transfected in the ECV304 cell line. The pcDNA3.1/HisB/LacZ plasmid (Invitrogen), containing the b-galactosidase gene under the control of a CMV promoter, was used as an internal standard. SEAP activity was measured in a plate fluorometer (Dynatech) using 4-methylumbelliferyl phosphate as a substrate, and normalized with respect to b-galactosidase activity. Results represent the mean of at least six transfection experiments for each construct.
Relative quantitative RT-PCR
We could obtain neocortical samples from seven aged nondemented subjects. All of them were hospitalized for various disorders and died in public hospitals. Samples of Brodmann area 9 (prefrontal cortex) were deep-frozen at autopsy (excluding patients with postmortem delay superior to 24 h) and subsequently stored at À801C. Total RNA was extracted from frozen samples using the TRIzol method (Invitrogen), following the manufacturer's instructions. In all, 1 mg of total RNA was reverse-transcripted using random hexamers and AMV-reverse transcriptase (Finnzymes), in a volume of 25 ml, following the manufacturer's protocol. A volume of 1 ml of this reaction was used in all subsequent PCRs. Amplification of ECE-1 cDNA was performed using the following primers: ECE-1F: 5 0 -AGT ATG ACA AGG ACG GGA ACC-3 0 and ECE-1R: 5 0 -CTT ACC AGA CTT CGC ACT TGT G-3 0 (resulting in a 459 bp product). Relative quantitative duplex PCRs were performed in a volume of 25 ml, using 18S RNA as an internal standard. 29 Each reaction contained ECE-1-specific primers and QuantumRNA Universal 18S primers (Ambion, resulting in a 315 bp product) in the same tube, following the manufacturer's instructions. We tested different 18S primer-to-competimer ratios and finally used ratios of 2 : 8 for ECE-1 relative quantification. PCR was performed using AmpliTaq Gold (Perkin-Elmer), with 9 min of denaturation at 951C, followed by 28 cycles comprising 30 s at 941C, 30 s at 621C, and 30 s at 721C (the optimal number of cycles had been determined as recommended). PCR products were loaded onto a 2% agarose gel, stained with ethidium bromide, and visualized by UV transillumination, using a CCD video camera. Raw images were directly saved as .tif files, and densitometric analysis was performed for each sample using the NIH Image software. For each subject, relative quantitative RT-PCR were performed and analyzed in triplicate, and the mean of the three experiments was used in subsequent tests.
Genetic association study
French Caucasian patients affected by LOAD were recruited in hospitals. All were thoroughly investigated. Clinical diagnosis of probable AD was made according to the DSM III R and NINCDS-ADRDA criteria. None of the subjects had a family history of AD consistent with Mendelian inheritance. Caucasian controls of similar ages were recruited in France and defined as subjects without DSM III R dementia ECE-1 and Alzheimer's disease B Funalot et al criteria and with integrity of their cognitive functions. The study was approved by the ethical committee of the institutions and written consent was obtained from all patients or from their relatives.
ECE1B C-338A and ECE1A G-377A genotypes were determined by PCR-RFLP techniques. Amplification primers were: 5 0 -tag ggt tat agg aga ggg ctc agg-3 0 and 5 0 -aag tat cag gaa ggt gcc ctc aat-3 0 for ECE1B C-338A, 5 0 -AGG AGG CCT GCC ACA CCC TGC-3 0 and 5 0 -ATG CAA CAC GAA GGC ACC TAC-3 0 for ECE1A G-377A. ECE1B amplicons were digested with the restriction endonuclease Tsp509I (New England Biolabs), the 446 bp PCR product containing either one (À338C) or two (À338A) restriction site(s) for Tsp509I. ECE1A amplicons were digested with the restriction endonuclease NlaIII (New England Biolabs), the 947 bp PCR product containing either one (À377G) or two (À377A) restriction site(s) for NlaIII. Digestion products were loaded onto submarine agarose gels and visualized by ethidium bromide staining.
ECE1B A-2460G genotype was determined by the TaqMan allelic discrimination method on an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Sequences of amplification primers were: 5 0 -GCC GGG TGA ATC CCT TAC AC-3 0 and 5 0 -TTT TGA AAA AGA AGT TCA GTT CAC AGA ACA-3 0 , sequences of hybridization probes were: 5 0 -ACC CAC ATG CCC CG-3 0 (allele A) and 5 0 -CCC ACG TGC CCC G-3 0 (allele G).
Statistics
Differences in mean alkaline phosphatase activity (promoter-reporter gene study) were assessed by two-tailed Student's t-test. Differences in neocortical ECE-1 mRNA expression levels between genotype groups were assessed by one-tailed Student's t-test. In the genetic association study, genotypic frequencies were compared by using Pearson's w 2 test. Multivariate logistic regression models were used to explore the effect of the ECE1B C-338A and ECE1A G-377A variants on AD risk. Statistical interactions between genotype and covariates (age, sex, ApoE genotype) were systematically explored. A P ¼ 0.05 level of statistical significance was used in all tests.
Results
ECE-1 expression in human cerebral cortex
We first performed immunocytochemical studies on various brain regions obtained from nondemented subjects and observed a neuronal ECE-1 immunoreactivity in the hippocampus as well as in various neocortical regions (Figure 1 ). In the neocortex, ECE-1 immunoreactivity was observed in frontal, parietal, temporal and occipital regions ( þ / þ þ ), mainly in pyramidal neurons of layers III and V (Figure 1a) . In the hippocampus, the subregional pattern of expression of ECE-1 was similar for all subjects, showing a weak immunoreactivity ( þ ) in the subiculum and CA1 field, contrasting with a marked staining ( þ þ þ ) of the pyramidal cells of the CA2, CA3, and CA4 fields (Figure 1b and c) . Negative controls showed no staining. A similar pattern of immunostaining was observed when using the B61/104 or the E15/6 monoclonal antibodies (Supplementary Figure 1) which strongly supports that this staining is specific of brain ECE-1. However, we cannot completely rule out that both antibodies could crossreact with ECE-2 (which has 60% homology with ECE-1). The pattern of expression of ECE-1 across the hippocampus appears to be inversely correlated with susceptibility to Ab deposition: it was previously shown that Ab deposition first occurs in the subiculum and CA1 field, whereas the CA2-CA4 fields are much more resistant to Ab deposits. 30 These different susceptibilities appear to be associated with striking differences in ECE-1 expression in the hippocampal fields.
Identification of a functional polymorphism in the ECE-1 gene In order to explore the hypothesis that the levels of ECE-1 expression could be genetically controlled and influence the risk of developing AD, we screened the ECE1 gene for common polymorphisms. The ECE-1 protein exists in four isoforms (ECE-1a, ECE-1b, ECE-1c, and ECE-1d), which only differ by their N-terminal amino-acid tails. [31] [32] [33] The different isoforms result from the existence of four alternative promoters in the ECE1 gene, each core promoter driving the transcription of one isoform (Figure 2a) . By direct gene sequencing, we identified a singlenucleotide polymorphism (C/A substitution) in the promoter region controlling ECE-1b-ECE-1d isoform transcription (Figure 2a ). Sequence analysis with the MatInspector program, using the TRANSFAC database of transcription factor-binding sites, 28 showed that presence of the variant (A allele) created a potential binding site for E2F transcription factors. Recently, the same genetic variant was independently identified by others as an E2F-binding site. 34 To confirm the functionality of this polymorphism, the influence of the C/A substitution on transcriptional activity was assessed using promoter-reporter gene experiments. We tested two promoter sequences of different sizes: the shorter one was limited to the 822 bp upstream from the ECE1-b first codon, whereas the larger one (1081 bp) also contained the ECE-1d core promoter (Figure 2a ). These promoter sequences were placed upstream from an alkaline phosphatase reporter gene, and the resulting constructs were transfected in ECV304 cells, which constitutively express ECE-1b and ECE-1d isoforms. 31 As shown in Figure 2b , presence of the A allele in the ECE-1b promoter alone was responsible for a 30% increase in reporter gene expression (Po0.001). When studying the larger genomic sequence containing the ECE-1d core promoter, presence of the A allele resulted in a much higher increase (300%) in reporter gene expression (Po0.001). Finally, we tested whether carrying the A allele increased ECE1 gene transcription in human prefrontal neocortex (Brodmann area 9). As shown in Figure 2c , we found a two-fold higher ECE-1 and Alzheimer's disease B Funalot et al level of ECE-1 mRNA expression in carriers (three AC subjects) as compared to noncarriers (four CC subjects; P ¼ 0.03). An obvious limitation of these last results is related to the small sample size, which will need to be increased in further studies. A concomitant study of ECE-1 protein and activity will also be of interest.
ECE1 polymorphisms and protection against AD
We next tested the hypothesis of a protective effect of the ECE1B C-338A variant against LOAD in a genetic association study comparing 401 subjects with sporadic LOAD and 461 age-and sex-matched controls.
Results of the genotyping are summarized in Immunostaining of an adjacent slide with an anti-CD68 monoclonal antibody confirmed that these additional ECE-1-positive structures are microglial cells.
ECE-1 and
homogeneous effect of the ECE-1 gene variant in subjects with or without ApoE4 allele(s). To strengthen this genetic association, we searched for other variants of the ECE1 gene that would influence the risk of AD. We identified an A/G polymorphism in public databases (rs213048 in dbSNP: http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?db ¼ Snp), located 2302 bp upstream from the ECE1B C-338A variant (ECE1B A-2640G). Genotyping of this polymorphism in 185 control individuals showed that ECE1B A-2640G and ECE1B C-338A are in perfect linkage disequilibrium, having the same allelic frequencies (frequency of the G allele of ECE1B A-2640G ¼ frequency of the A allele of ECE1B C-338A ¼ 0.29) and genotypic distributions. Comparison with the chimpanzee genomic sequence (http:// www.ensembl.org/Pan_troglodytes/) indicated that the À2640G/À338A association represents the ancestral haplotype, so that genotyping the ECE1B C-338A variant appears equivalent to determining the presence or absence of the ancestral haplotype at this locus. By direct gene sequencing, we identified another genetic variant (ECE1A G-377A), located B11 kilobases (kb) downstream from the ECE1B C-338A variant, in the ECE-1a-specific promoter region. Sequence analysis with the MatInspector program indicated no change in transcription factor-binding sites. ECE1A G-377A genotypes in the patients and controls are showed in Table 1 . We observed a strong LD between ECE1B C-338A and ECE1A G-377A (D 0 ¼ 0.824) and a reduced frequency of A allele carriers in the patients' group (P ¼ 0.03). The combination of AA homozygosity at the ECE1B C-338A polymorphism and presence of at least one A allele at the ECE1A G-377A polymorphism was associated with the maximal risk reduction (OR ¼ 0.39, 95% CI 0.16-0.95 after adjustment), but it should be kept in mind that this last result relies on a small number of controls (n ¼ 22) and patients (n ¼ 9).
Discussion
Ab is continuously synthesized in all human tissues, but in the absence of a genetic disease deposition of aggregated Ab in brain only occurs in aged subjects. In situ Ab degradation by endopeptidases might play a major role in Ab clearance, 9,10 but proteases responsible for this degradation in human brain still have to be characterized. Several candidates have been suggested, among which are angiotensin-converting enzyme (ACE), some matrix metallopeptidases, plasmin, thrombin, and other proteases. 9, 10 To date, only neprilysin, ECE-1, ECE-2, and insulysin have been shown to influence brain Ab levels when examined in knockout mice. [11] [12] [13] [14] 35, 36 The pattern of expression of ECE-1 observed in human neocortex and hippocampus (Figure 1 ) further suggests that this enzyme is involved in physiological degradation of Ab in human cerebral cortex throughout life.
We showed that homozygosity for a regulatory polymorphism in the ECE1 gene (ECE1B C-338A) could protect against LOAD. A threshold effect could explain why AA subjects are protected against LOAD, whereas AC subjects are not: the A allele being associated with increased ECE1 promoter activity, AA homozygotes are expected to have the highest levels of ECE-1 expression. However, we could not obtain direct evidence of this in our expression study: we found increased ECE-1 mRNA expression in the brain of AC heterozygotes, but unfortunately we had no brain tissues from AA homozygotes for our experiments (this genotype being the rarest in Caucasian populations).
Our findings were strengthened by the study of two other variants of the ECE1 gene, showing that the association with AD risk extends over at least 13 kb of the gene sequence. It will now be important to assess the effect of ECE1 genetic variation in other populations, in particular with different genetic backgrounds. Hence, our findings offer the opportunity to evaluate a novel genetic locus as a modifier of LOAD risk. Multiple genes are probably involved in the genetic predisposition to LOAD, and identification of an increasing number of these genes should markedly increase prediction of disease. 37 Beyond the fact that variation in the ECE1 gene may modulate LOAD genetic risk, the results of our genetic association study can also be viewed as the first functional evidence of the involvement of ECE-1 in LOAD pathogenesis. The resulting ORs of 0.4-0.5 indicate a protection of magnitude similar to that conferred by the ApoE2 allele. 38 Interestingly, ApoE genotype also seems to influence Ab clearance. 8, 9 Altogether, these results reinforce the hypothesis that variations in Ab clearance influence the risk of LOAD.
At a subcellular level, it is noteworthy that the two ECE-1 isoforms for which we demonstrate a transcriptional control by the ECE1B C-338A variant (ECE-1b and ECE-1d, Figure 2b ) are targeted to the endosomal system. 39 BACE-1 is also targeted to the endosomal system, 40 and the results of several groups support an important role for this intracellular compartment in Ab production. [41] [42] [43] In addition, endocytic pathway abnormalities have been shown to precede Ab deposition in the brains of patients affected by sporadic AD. 44 Finally, our findings also offer new therapeutic options in AD. Indeed, the results of the genetic association study suggest that a limited increase in ECE-1 activity could prevent, or delay, up to half of LOAD cases. One means of enhancing ECE-1 activity would be an upregulation of the gene transcription, notably via the E2F pathway. Alternatively, the use of allosteric activators of the enzyme or even gene therapy may become realistic in a next future. All these opportunities make ECE-1 a new potential target for AD therapeutic intervention. 
